Concepedia

Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers

Martin Gutierrez, Robin Guo, Giuseppe Giaccone, Stephen V. Liu, Zhonglin Hao, Christie Hilton, James M. Hinson, Mark G. Kris, Everardus Orlemans, Alexander Drilon

Lung Cancer · 2021 · 25 citations · 8 references

DOIFull text

Open access

Concepts

References

8

Proteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasis

Andrija Finka, Pierre Goloubinoff · Cell Stress and Chaperones · 2013 · 228 citations · Full text

, , +17

Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents

Kenneth H. Huang, James M. Veal, R. Patrick Fadden et al. · Journal of Medicinal Chemistry · 2009 · 191 citations · Full text

, , +15

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours

Jeffrey R. Infante, Glen J. Weiss, Suzanne F. Jones et al. · European Journal of Cancer · 2014 · 55 citations

, , +9

Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer

Hanqing Liu, Junjie Lu, Yingqi Hua et al. · Cell Death and Disease · 2015 · 43 citations · Full text

, , +16

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models

Shu‐Fu Lin, Jen‐Der Lin, Chuen Hsueh et al. · Oncotarget · 2017 · 39 citations · Full text

, , +17